Compare · BDSX vs CNC
BDSX vs CNC
Side-by-side comparison of Biodesix Inc. (BDSX) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $34.83B, about 133.6x BDSX ($260.7M).
- CNC has been more active in the news (14 items in the past 4 weeks vs 3 for BDSX).
- CNC has more recent analyst coverage (25 ratings vs 9 for BDSX).
- Company
- Biodesix Inc.
- Centene Corporation
- Price
- $23.58-4.69%
- $69.14-1.98%
- Market cap
- $260.7M
- $34.83B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 14
- Recent ratings
- 9
- 25
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BDSX
- Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
- Chairman Patience John converted options into 1,360 shares, increasing direct ownership by 5% to 26,743 units (SEC Form 4)
- Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
- Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
- Biodesix to Participate in Upcoming Investor Conferences
- Emeritus Director Schuler Jack W bought $366,992 worth of shares (15,000 units at $24.47) (SEC Form 4)
- Emeritus Director Schuler Jack W bought $665,940 worth of shares (27,600 units at $24.13) (SEC Form 4)
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces Second Quarter 2026 Results and Highlights
Latest CNC
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
- Centene to Launch Nationwide Gold Card Program for Qualifying Providers
- SEC Form 8-K filed by Centene Corporation
- Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
- Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
- Director Tyler Lauren M was granted 482 shares, increasing direct ownership by 15% to 3,698 units (SEC Form 4)
- Director Tanji Kenneth was granted 603 shares, increasing direct ownership by 5% to 13,093 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 583 shares, increasing direct ownership by 2% to 25,796 units (SEC Form 4)